InvestorsHub Logo
Followers 26
Posts 1778
Boards Moderated 0
Alias Born 06/15/2018

Re: Bearslayer post# 20033

Friday, 12/31/2021 5:51:02 AM

Friday, December 31, 2021 5:51:02 AM

Post# of 22611
Nice! Their patent portfolio alone should value this well over $100 million market cap. Compare to other clinical stage biopharma stocks like Myovant and Tarsus trading on NYSE and Nasdaq. Vyome has a larger patent portfolio than both of those companies. Expecting a massive move toward a proper valuation when all comes to light.